HALIFAX, Dec. 16 /PRNewswire-FirstCall/ - MedMira Inc. (“MedMira”) the global market leader in premium rapid diagnostic solutions, today announced that it will host a conference call with analysts to discuss the company’s first quarter financial results beginning at 9:00 a.m. Eastern Standard Time (10:00 a.m. Atlantic) on Tuesday, December 20, 2005. The call will be preceded by the release of the company’s first quarter financial results the previous evening and they will be available on the MedMira web site www.medmira.com
In order to listen to the conference call, please either dial 800-814-4862 for toll-free anywhere in Canada or the USA, or 416-644-3423 in the Toronto area.
A replay of the call will be available until 23:59 EST Tuesday, December 27, 2005 and may be accessed by dialing 877-289-8525 for toll-free anywhere in Canada or the USA, or 416-640-1917 in the Toronto area and entering the pass code: 21168765 followed by the number sign anytime after the call has been ended.
About MedMira
MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira’s tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People’s Republic of China have approved MedMira’s Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMira’s Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test, MedMira’s over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People’s Republic of China.
MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira’s website at www.medmira.com.
MedMira Inc.
CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail:ir@medmira.com; Andrea Young, Corporate Communications, Tel. (902)450-1588, Email: ayoung@medmira.com
